Etalanetug reduces CSF tau biomarkers in dominantly inherited Alzheimer's disease in phase 1b/2 study
Can a new drug slow Alzheimer's toxic tau protein in the brain?
This open-label phase 1b/2 study in 8 participants with mild-to-moderate cognitive impairment due to dominantly inherited Alzheimer's diseas…
An early study shows an experimental drug lowers two key tau proteins in spinal fluid for people with a rare inherited form of Alzheimer's.
Plasma biomarkers diverge sequentially up to 26 years before symptom onset in autosomal dominant Alzheimer's disease
Can a blood test spot Alzheimer's risk decades before symptoms appear?
A longitudinal cohort study of 73 ADAD mutation carriers and 40 non-carriers found eight plasma biomarkers elevated sequentially from 26 to …
A blood test can spot Alzheimer's risk up to 26 years before symptoms appear in people with a specific inherited gene mutation.
CSF protein changes in autosomal dominant Alzheimer's disease show inflammatory markers follow amyloid and tau abnormalities
Study maps protein changes in inherited Alzheimer's disease before symptoms appear
An observational study of 484 participants with pathogenic PSEN1, PSEN2, and APP mutations from the DIAN network analyzed 972 CSF samples.
Inherited Alzheimer's shows inflammation and brain damage appearing after amyloid and tau changes, proving a multi-protein test predicts sym…